Europe — EMA
Mertioscan (Mertiatide)
GNH USA supplies Mertioscan (Mertiatide), a peptide therapeutic for investigational use. Request a quote for global supply.
Request sourcing
What is Mertiatide?
Mertiatide, the active ingredient in Mertioscan, is a peptide presented as an intravenous solution for infusion use. It is being investigated for potential therapeutic applications in specific disease contexts. GNH USA supplies Mertioscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.
What is Mertiatide used for?
Mertioscan (mertiatide) currently has no publicly disclosed approved indications.
What are the side effects of Mertiatide?
Adverse‑reaction information for Mertioscan is limited in the public domain.
Common Side Effects: - None reported in publicly available sources.
Serious or Rare Side Effects: - None reported in publicly available sources.
What precautions apply to Mertiatide?
When handling Mertioscan, consider general safety principles for intravenous biologics. - Patient monitoring: Observe for any unexpected clinical changes during infusion. - Compatibility: Verify compatibility with IV fluids before administration. - Infusion rate: Follow institutional protocols to avoid rapid administration. - Allergy assessment: Screen for known hypersensitivity to peptide products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Mertiatide interact with?
No specific drug‑interaction data have been published for mertiatide.
Major Interactions (Avoid): - None identified in the literature.
Moderate Interactions (Monitor Closely): - Concomitant use of other investigational peptides: monitor for additive immunologic effects. - Immunosuppressants: observe for altered immune response. - Anticoagulants: watch for changes in coagulation parameters during infusion.
